News Sentiment

KZIA sentiment intelligence

Kazia Therapeutics Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.56 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+2.3% over one week, -5.0% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 2.3% Price confirming higher
Trend fit Trend active -5.0% over four weeks
Fair value -15.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 29
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 7
TradingKey 7
Moomoo 6
TradingView 3
simplywall.st 2
StockStory 1
Investing.com 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 12
Analyst action 7
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
Stock Titan Direct company coverage

Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director

Kazia Therapeutics (KZIA) has granted 100,000 employee stock options over ADSs to David Cain, its Director, CMC. The options have an exercise price of $9.10 per ADS and will vest in tranches, starting January 8, 2027, and expiring on January 8, 2029. This equity grant aims to pro

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 05:12
Source
Stock Titan
Stock Titan Direct company coverage

Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78

Kazia Therapeutics director Robert F. Apple was granted 75,000 stock options over ADSs on January 8, 2026, with an exercise price of $6.78 per ADS. These options, awarded for no cash consideration, will vest on January 8, 2027, and have an expiration date of January 8, 2029. This

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Kazia Therapeutics (KZIA) grants director 100,000 stock options

Kazia Therapeutics director Steven R. S. Coffey was granted 100,000 employee stock options over ADSs with an exercise price of $9.10 per ADS. The options were granted for no consideration, vest on January 8, 2027, and expire on January 8, 2029. This transaction was approved by th

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance

Kazia Therapeutics reported that Jeffrey Bonacorda, VP, Finance and Controller, received a grant of 150,000 employee stock options (ADSs). These options have an exercise price of $6.78 per ADS, based on the Nasdaq closing price on January 8, 2026, and will vest over three years s

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant

KAZIA THERAPEUTICS LTD CEO John E. Friend II was granted 150,000 restricted share units (RSUs) and 500,000 employee stock options. These equity compensation awards, approved by the Remuneration Committee, involve an exercise price of $6.78 per ADS for the options and a vesting sc

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
Moomoo Direct company coverage

BTIG Initiates Kazia Therapeutics at Buy With $34 Price Target

BTIG has initiated coverage of Kazia Therapeutics (NASDAQ: KZIA) with a Buy rating and a price target of $34. This rating indicates a strong positive outlook for the company's stock by the investment firm.

Tone
Positive 70/100
Event
Analyst action
Published
02 Jul 2026 03:09
Source
Moomoo
Moomoo Direct company coverage

BTIG Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $34

BTIG has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating. The firm has set a price target of $34 for the pharmaceutical company. This new rating suggests a positive outlook from BTIG on Kazia Therapeutics' stock performance.

Tone
Positive 75/100
Event
Analyst action
Published
01 Jul 2026 14:40
Source
Moomoo
Investing.com Canada Direct company coverage

BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com

BTIG has initiated coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and a price target of $34.00, citing the company's advanced oncology pipeline, particularly its drug paxalisib. While the stock has seen a significant return in the past year, InvestingPro suggests

Tone
Positive 74/100
Event
Analyst action
Published
01 Jul 2026 11:16
Source
Investing.com Canada
TradingView Direct company coverage

Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA)

Kazia Therapeutics Ltd (NASDAQ:KZIA) financial data, including actual results and analyst estimates, is available on TradingView. The platform allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. Us

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 18:10
Source
TradingView
Stock Titan Direct company coverage

KZIA SEC Filings - Kazia Therapeuti 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Kazia Therapeutics (KZIA) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It features AI-generated summaries, impact scoring, and sentiment analysis for each filing. Recent fil

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Kazia Therapeutics (KZIA) grants CFO 200,000 options vesting to 2029

Kazia Therapeutics reported that its CFO, James E. Levine, was granted 200,000 employee stock options over ADSs with an exercise price of $13.86 each. The options have a vesting schedule, with one-third vesting on June 1, 2026, and the remainder vesting annually thereafter, expir

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 23:11
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks

This article lists Exchange Traded Funds (ETFs) that invest in Kazia Therapeutics Ltd Sponsored ADR stocks, presenting them as a way to invest in the company with lower risk. It provides a table detailing fund information such as market value, weight, issuer, management style, ex

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 04:10
Source
TradingView
TradingKey Direct company coverage

Kazia Therapeutics Ltd (KZIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Kazia Therapeutics Ltd (KZIA), categorizing its performance by business segments and regional contributions. As of the report updated on March 4, 2025, relevant financial data for FY2021 and FY2022 concerning these breakdowns have not

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 05:10
Source
TradingKey
TradingKey Direct company coverage

Kazia Therapeutics Ltd (KZIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Kazia Therapeutics Ltd (KZIA), detailing its current stock price, market cap, and various technical indicators. It outlines signals from MACD, RSI, KDJ, and Moving Averages, suggesting a "Buy" signal based on current technical analysi

Tone
Positive 74/100
Event
Market update
Published
18 Jun 2026 22:39
Source
TradingKey
TradingKey Direct company coverage

Kazia Therapeutics Ltd (KZIA) Shareholder Structure: Major Shareholders & Institutional Holdings

The article provides a detailed breakdown of Kazia Therapeutics Ltd's (KZIA) shareholder structure, listing major individual and institutional holders. It highlights that Jorey Chernett is the largest individual shareholder with 14.80%, while Alyeska Investment Group, L.P. is a s

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 16:40
Source
TradingKey
TradingKey Direct company coverage

Kazia Therapeutics Ltd (KZIA) Institutional Confidence

This article provides details on the institutional confidence score for Kazia Therapeutics Ltd (KZIA), indicating a current score of 0.00 with no change from the previous score. It lists key institutional shareholders and their holdings, such as Chernett (Jorey) with a significan

Tone
Positive 67/100
Event
Market update
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

Kazia Therapeutics Ltd (KZIA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Kazia Therapeutics Ltd (KZIA), detailing various volatility, financial, and investment risk metrics. It includes data points such as Beta vs S&P 500 index, VaR, maximum drawdown, realized volatility, and Sharpe Ratio across different ti

Tone
Negative 39/100
Event
Market update
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

Kazia Therapeutics Ltd (KZIA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Kazia Therapeutics Ltd (KZIA), including future EPS and revenue growth estimates. Based on an analysis of 4 analysts, the consensus target price for KZIA is USD 26.25, suggesting a 90.63% upside. The report highlights a "Buy" trend f

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 04:40
Source
TradingKey
TradingKey Direct company coverage

Kazia Therapeutics Ltd (KZIA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Kazia Therapeutics Ltd (KZIA), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The article also provides the stock's current pri

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 04:40
Source
TradingKey
Stock Titan Direct company coverage

Kazia Therapeutics (KZIA) CFO James E. Levine files initial Form 3

Kazia Therapeutics' new Chief Financial Officer, James E. Levine, has filed an initial Form 3 with the SEC, indicating his beneficial ownership status. The filing clarifies his position as a reporting officer but shows no reported purchases, sales, or other transactions of KZIA s

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:40
Source
Stock Titan
Moomoo Direct company coverage

H.C. Wainwright Maintains Kazia Therapeutics(KZIA.US) With Buy Rating, Maintains Target Price $18

H.C. Wainwright has reiterated its Buy rating for Kazia Therapeutics (KZIA.US), maintaining a price target of $18. This continued endorsement suggests the firm's confidence in the company's future performance and valuation. The decision to uphold both the rating and the price tar

Tone
Positive 76/100
Event
Analyst action
Published
07 Jun 2026 01:09
Source
Moomoo
Stock Titan Direct company coverage

Kazia Therapeutics (KZIA) director details existing ADS option grants

Kazia Therapeutics director Ebru Davidson has filed an initial ownership report (Form 3) detailing her existing option grants for the company's American Depositary Shares (ADSs). The filing reveals two ADS option positions, one for 75,000 ADSs with an exercise price of $8.00 and

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 00:39
Source
Stock Titan